Insilico's AI-designed drug shows 3-4 years of biological age reversal in Phase IIa trial
Kyrannio · x · 2026-10-05
- Rentosertib, discovered and designed by Insilico Medicine's AI (target TNIK identified by AI, molecule designed by generative AI), originally developed for idiopathic pulmonary fibrosis, produced a striking secondary result in humans.
- In a 42-patient Phase IIa trial, all 6 proteomic aging clocks measured patients as biologically younger after treatment.
- The strongest regimen showed roughly 3-4 years of predicted biological age reversal after just four weeks, with one clock indicating as much as 6 years.
- A notable data point for the "AI will solve aging" narrative, though it is a secondary analysis in Phase IIa, not a primary endpoint.
Related event: AI-Designed Drug Shows 3-4 Years of Biological Age Reversal in Human Trial(3 posts)→
More from Apps
- This Agent Ships a Brand-New Puzzle Game Every Day — RichardsonDx · 2026-11-20
- Amazon Connect Talent: AI Interviews Match Expert Scoring 89% of the Time — AWS ML Blog · 2026-11-20
- Rippling AI lets any employee prompt their way to custom business tools — andreisavu · 2026-11-20
- ChapterPal positions itself as the home of AI-assisted, auto-updated textbooks — burkov · 2026-11-20
- Canva ships an AI off switch, letting users disable generative AI features — pbaylies · 2026-11-20
- Consultant runs Gemini as a coworker for 3 months: email triage, lead capture, pair programming — McDonaghMatthew · 2026-11-20